Certara Appoints Justin Edge as President of its Synchrogenix Division

February 4, 2019

Global pharma and healthcare executive joins Certara to support the increasing scale, scope and breadth of its emerging regulatory science opportunities

PRINCETON, NJ – February 4, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that Justin Edge has joined Certara as President of Synchrogenix, the company’s regulatory science division. Justin comes to Certara from GfK, a leading global research and analytics firm with 13,000 employees, where he most recently led the company’s healthcare business unit, managing teams in more than 20 countries.

“With innovations occurring at breathtaking speed in science today and the global nature of our marketplace, regulatory science expertise has never been more important,” said Certara CEO Dr. Edmundo Muniz. “As the healthcare industry concludes a year of record-breaking numbers and complex types of newly-approved therapies, we at Certara recognize the need to expand our staff and portfolio of offerings. It is with great pleasure that I welcome Justin to Certara. Our customers will benefit from his global expertise and healthcare consulting experience.”

“This is an exciting time for Synchrogenix, and I look forward to working with Kelley Kendle in her new role as Strategic Solutions Officer at Certara and the rest of the team to support our growing customer base,” said Justin Edge. “Together, we will help to ensure that regulatory science continues to progress in tandem with today’s science and technology advances, including cell and gene therapies, genomics-based diagnostics, innovative drug-device combinations, and the increasing use of real-world evidence and artificial intelligence.”

Certara’s Synchrogenix division provides a wide range of services and technologies to support sponsors throughout the regulatory process, including developing and submitting all the requisite documents for new drug, medical device and biologics applications. In addition, the team has been a pioneer in adopting cutting-edge technologies, including its AI-natural language processing software for meeting transparency and disclosure regulations and its blockchain type distributed-ledger technology to address the increasingly data-rich and complex challenges in clinical research and regulatory reporting.

About Certara
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration. As a result, it optimizes R&D productivity, commercial value and patient outcomes. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. For more information, visit www.certara.com.

Certara Contact:
Ellen Leinfuss, 609-216-9586
Chief Commercial Officer

Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com